Coherus Biosciences (CHRS) Rating Lowered to Sell at BidaskClub

Coherus Biosciences (NASDAQ:CHRS) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other equities analysts have also weighed in on CHRS. Zacks Investment Research lowered shares of Coherus Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. ValuEngine lowered shares of Coherus Biosciences from a “sell” rating to a “strong sell” rating in a research report on Thursday, October 26th. Finally, Citigroup restated a “buy” rating and set a $23.00 price objective on shares of Coherus Biosciences in a research report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $29.67.

Coherus Biosciences (CHRS) opened at $9.95 on Friday. Coherus Biosciences has a 52 week low of $8.05 and a 52 week high of $27.70. The company has a debt-to-equity ratio of 1.84, a quick ratio of 5.46 and a current ratio of 5.46. The company has a market cap of $576.56, a PE ratio of -1.84 and a beta of 3.81.

Coherus Biosciences (NASDAQ:CHRS) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative net margin of 73.89% and a negative return on equity of 582.31%. equities research analysts forecast that Coherus Biosciences will post -4.39 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in CHRS. Schwab Charles Investment Management Inc. boosted its holdings in shares of Coherus Biosciences by 20.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 161,366 shares of the biotechnology company’s stock worth $2,316,000 after buying an additional 27,064 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Coherus Biosciences by 2.8% in the second quarter. Bank of New York Mellon Corp now owns 169,840 shares of the biotechnology company’s stock worth $2,437,000 after buying an additional 4,700 shares during the period. Legal & General Group Plc boosted its holdings in shares of Coherus Biosciences by 12.6% in the second quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock worth $134,000 after buying an additional 1,046 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Coherus Biosciences by 1.4% in the second quarter. Principal Financial Group Inc. now owns 140,390 shares of the biotechnology company’s stock worth $2,015,000 after buying an additional 1,950 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in shares of Coherus Biosciences by 0.9% in the second quarter. Wells Fargo & Company MN now owns 29,116 shares of the biotechnology company’s stock worth $418,000 after buying an additional 253 shares during the period. Institutional investors own 81.48% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.com-unik.info/2018/02/03/coherus-biosciences-chrs-rating-lowered-to-sell-at-bidaskclub.html.

About Coherus Biosciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit